LABS — Life Science Reit Cashflow Statement
0.000.00%
Last trade - 00:00- £150.85m
- £272.53m
- £20.31m
Annual cashflow statement for Life Science Reit, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 7.73 | -26.9 | -14.6 | -7.79 | -14.6 |
| Non-Cash Items | -8.12 | 31.3 | 23.2 | 17.4 | 23.2 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.92 | -5.46 | -0.961 | 3.33 | 7.62 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 3.54 | -1.09 | 7.62 | 12.9 | 7.62 |
| Capital Expenditures | — | -7.64 | -24 | -19.3 | -24 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -182 | -179 | 12.4 | 2.93 | 9.09 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -182 | -186 | -11.6 | -16.4 | -11.6 |
| Financing Cash Flow Items | -6.06 | -4.39 | -10.5 | -12.3 | -10.5 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 344 | 67.1 | -27.2 | -5.34 | -27.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 166 | -120 | -31.3 | -8.77 | -31.3 |